High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Implications for Differentiating Agents in APL and Metabolic Syndrome.
Publication/Presentation Date
6-1-2011
Abstract
BACKGROUND: Between January 1999 and December 2008, 469 patients treated for acute myeloid leukemia (AML) were included in this single-institution study.
METHODS: We performed a case-control analysis to study the rate of obesity among patients with acute promyelocytic leukemia (APL) and non-APL AML.
RESULTS: A total of 81% of APL patients analyzed were obese compared with 41.7% in the non-APL group (p < 0.001). Body mass index (BMI) >30 was seen in 57% of APL patients compared with 31% for the non-APL group (p = 0.01). Neither obesity nor the chemotherapy dosing based on ideal body weight affected survival.
CONCLUSIONS: Our findings generate the hypothesis that APL and metabolic syndromes may share a common pathogenic pathway via retinoic acid receptors (RARs), the ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth and survival. If this link is confirmed in larger studies, our data will instigate further studies using RXR and RAR modulators as a preventive strategy among obese individuals.
Volume
2
Issue
3
First Page
141
Last Page
145
ISSN
2040-6207
Published In/Presented At
Tedesco, J., Qualtieri, J., Head, D., Savani, B. N., & Reddy, N. (2011). High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Implications for Differentiating Agents in APL and Metabolic Syndrome. Therapeutic advances in hematology, 2(3), 141–145. https://doi.org/10.1177/2040620711408490
Disciplines
Medicine and Health Sciences
PubMedID
23556085
Department(s)
Department of Pathology and Laboratory Medicine
Document Type
Article